SUNNYVALE, Calif.--()--Elixir Medical Corporation, a privately held medical company, announced today that Motasim Sirhan, President and Chief Executive Officer, will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation will be held on Monday, January 7, 2013 at 8:30 a.m. PST (11:30 a.m. EST) at the Westin St. Francis.
About Elixir Medical
Elixir Medical Corporation develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions.
The company’s initial area of focus is coronary vascular intervention, with a broad portfolio of products leveraging Elixir’s unique pharmaceutical, drug release, stent platform, and scaffold technologies:
- DESolve™: Fully resorbable vascular scaffold currently in follow-up phase of the CE Mark trial
- DESyne BD™: CE Mark-approved degradable coating drug eluting stent (DES)
- DESyne™: CE Mark-approved durable polymer coated DES
Elixir is also developing resorbable scaffolds for peripheral vascular indications. The peripheral program is currently in the pre-clinical phase.
For more information, on the company and its products, please visit www.elixirmedical.com.